The attrition rate of drug programs in early-stage development is high, with two-thirds of preclinical programs failing to move successfully to Phase 1. How do we better inform translational R&D decisions to de-risk investments and help increase probability of success?
Physiologically-based pharmacokinetic (PBPK) modeling and simulation is a regulatory-adopted, versatile tool in drug development that helps answer a myriad of “what if” questions without clinical testing. PBPK can also be used by discovery and translational scientists to increase confidence for pre-IND decisions, including:
- First-in-human dose prediction
- Early drug-drug interaction screening
- Compound prioritization and selection
- Early formulation work
Join this webinar to learn about using PBPK software, Simcyp Discovery Simulator for first-in-human dose prediction to help avoid the valley of death, crossing from preclinical to clinical research.